CN114652854B - Double-lock MOF material and preparation and application thereof - Google Patents

Double-lock MOF material and preparation and application thereof Download PDF

Info

Publication number
CN114652854B
CN114652854B CN202210208303.7A CN202210208303A CN114652854B CN 114652854 B CN114652854 B CN 114652854B CN 202210208303 A CN202210208303 A CN 202210208303A CN 114652854 B CN114652854 B CN 114652854B
Authority
CN
China
Prior art keywords
double
lock
zif
ultrapure water
rhodamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210208303.7A
Other languages
Chinese (zh)
Other versions
CN114652854A (en
Inventor
王英文
张盾
戚鹏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Oceanology of CAS
Original Assignee
Institute of Oceanology of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Oceanology of CAS filed Critical Institute of Oceanology of CAS
Priority to CN202210208303.7A priority Critical patent/CN114652854B/en
Publication of CN114652854A publication Critical patent/CN114652854A/en
Application granted granted Critical
Publication of CN114652854B publication Critical patent/CN114652854B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention belongs to the field of nano materials and biomedicine, and particularly relates to a double-lock MOF material, and preparation and application thereof. The double-lock MOF material takes ZIF-90 as a core, and the outer part of the material wraps acid sensitive hydrogel to form the double-lock MOF material with a shell-core structure and double-lock response. The double-lock MOF material prepared by the invention has excellent acid and ATP simultaneous stimulus response release performance. The double-lock MOF prepared by the invention has good stability and biocompatibility, and has wide application prospect in aspects of drug delivery and disease treatment.

Description

Double-lock MOF material and preparation and application thereof
Technical Field
The invention belongs to the field of nano materials and biomedicine, and particularly relates to a double-lock MOF material, and preparation and application thereof.
Background
Bacterial colonization on the surface and subsequent biofilm formation are one of the critical global issues. Biofilms are complex communities of microorganisms in extracellular polysaccharide matrices that adhere irreversibly to material surfaces, resulting in biofouling and wound infection. At present, the most common strategy for combating biofilms is the use of antibacterial drugs, however, due to lack of targeting and selectivity for biofilms, the use of excessive amounts of drugs leads to the emergence of drug resistant bacteria and increased off-target toxicity.
Nanocarrier-based antibiotic delivery systems are of great interest because of their ability to overcome toxicity caused by non-selective accumulation and to increase bioavailability of antibiotics. The nano-carrier is modified by the stimulus response surface, so that the selective targeted cargo release can be realized. However, single-stimulus nanocarriers sometimes cannot effectively identify biofilm areas due to the complex internal environment of the human body. For example, when acidic pH is used as an indicator of biofilm, acidic organelles or other external acid stimuli may also trigger cargo release, thereby increasing off-target toxicity and potential safety issues. Therefore, further improvement of the targeting efficiency of the biological membrane is crucial for accurate medical treatment and imaging, the nano-carriers at present relate to a wide range of nano-materials such as silica nano-particles, carbon nano-tubes, gold nano-particles and quanta, liposomes and polymers, but are only responsive to a single stimulus, no nano-carriers which continuously respond to two stimuli are found yet, and the pH/ATP double-lock nano-carrier provides a promising method for solving the problem.
Disclosure of Invention
The invention aims to provide a double-lock MOF material, and preparation and application thereof, aiming at the problem that the existing biological film area can not be effectively identified.
In order to achieve the above purpose, the invention adopts the following technical scheme:
a double-lock MOF material takes ZIF-90 as a core, and the outer part of the core is wrapped with acid-sensitive hydrogel to form a double-lock MOF material with a shell-core structure and double-lock response.
The hydrogel shell is prepared by mixing polyacrylic acid, calcium chloride and sodium carbonate according to a molar ratio of 1:1:1, and then reacting for 2-2.5 hours at normal temperature (22-25 ℃).
The dual-lock MOF material core is ZIF-90 generated by the normal temperature reaction of 2-formaldehyde imidazole and zinc acetate.
The ZIF-90 is prepared by mixing 2-formaldehyde imidazole and zinc acetate according to a molar ratio of 10:1, and then reacting for 30-35 minutes at normal temperature (22-25 ℃).
A preparation method of a double-lock MOF material comprises the steps of reacting 2-formaldehyde imidazole with zinc acetate at normal temperature to obtain ZIF-90, and then mixing the ZIF-90 with polyacrylic acid and calcium chloride to obtain the double-lock MOF material with double-lock corresponding to the acid-sensitive hydrogel, wherein the acid-sensitive hydrogel is a shell-core structure with the ZIF-90 wrapped inside a shell.
The material relation ratio of ZIF-90 to polyacrylic acid and calcium chloride is 1:2:2-1:2.5:2.5.
Use of a double-lock MOF material for the delivery of a drug. Further, the use of said materials in drug delivery and in tumor therapy.
According to the invention, 2-formaldehyde imidazole and zinc acetate react at normal temperature to generate the MOF material, fluorescent dye is wrapped in the MOF, and acid stimulus response hydrogel generated by the reaction of polyacrylic acid and calcium chloride is wrapped on the surface of the MOF to form the double-lock MOF material, so that the prepared double-lock MOF material has excellent acid and ATP continuous stimulus response release performance. Wherein, the ZIF-90 is internally wrapped with a fluorescent dye Rho 6G to confirm the stimulus response performance of the double-lock MOF material.
The invention has the beneficial effects that:
according to the invention, 2-formaldehyde imidazole and zinc acetate react at normal temperature to generate an MOF material core, fluorescent dye is wrapped in the MOF core, and acid stimulus response hydrogel generated by the reaction of polyacrylic acid and calcium chloride is wrapped on the surface of the MOF to form a double-lock MOF material, so that the prepared double-lock MOF material has excellent acid and ATP continuous stimulus response release performance. In the simulated biological membrane microenvironment, the double-lock MOF material shows good stimulus response, and the double-lock MOF nano-carrier prepared by the invention has the continuous stimulus response performance of acid response and ATP response due to the special shell-core structure, has good stability and selectivity, and is not easy to be interfered by complex environments. Has wide application prospect in the aspects of drug delivery and disease treatment.
The double-lock MOF has great potential in the aspect of double-stimulus response release, and can be further used for drug delivery and biomembrane eradication.
Drawings
FIG. 1 is a TEM image of a double-lock MOF provided in embodiment 1 of the present invention, wherein A is rhodamine 6G@ZIF-90, and B is rhodamine 6G@ZIF-90@ACC/PAA;
fig. 2 is a TEM image of the stimulus response of the double-lock MOF provided in example 1 of the present invention, wherein a is the double-lock MOF reacted in a solution with ph=4.0 for 15min, B is the double-lock MOF reacted in a solution with ph=4.0, 1mm ATP for 15min;
FIG. 3 is a graph showing the change of fluorescence values at different pH treatments of the double-lock MOF according to the embodiment of the present invention;
FIG. 4 is a graph showing the change of fluorescence values of double-lock MOFs in the acidic environment where ATP is treated at different concentrations according to the embodiment of the present invention;
FIG. 5 is a graph showing the change of fluorescence values of nanocarriers according to different assembly methods.
Detailed Description
The following description of the embodiments of the present invention is further provided in connection with the accompanying examples, and it should be noted that the embodiments described herein are for the purpose of illustration and explanation only, and are not limiting of the invention.
According to the invention, by forming the nano double-lock MOF with a specific shell-core structure, the nano carrier has the performance of continuous stimulus response of acid response and ATP response, has good stability and selectivity, and is not easy to be interfered by complex environments.
Example 1:
preparation of double-lock MOF:
1) 48.05mg of 2-imidazole-formaldehyde (0.5M), 4.79mg of rhodamine 6G (1 mM) were dissolved in 10.0mL of DMF and stirred for 15min, followed by slow addition of 5.0mL of DMF containing 0.05M zinc acetate. Then washed sequentially with DMF, ultrapure water and ethanol, and centrifuged (10000 rpm,5 min). Finally, the product was dispersed in ultrapure water to give rhodamine 6G@ZIF-90 stock solution (100 mg mL) -1 ). (see FIG. 1A).
2) 114mg polyacrylic acid (PAA, 0.1M), 111mg calcium chloride (0.1M) and 500. Mu.L rhodamine 6G@ZIF-90 (100 mg mL) -1 ) Added to 10.0mL of ultrapure water and stirred for 1 hour. Then, 10.0mL of 0.1M Na was added 2 CO 3 The solution was added rapidly and stirred for 1h. The resultant product was centrifuged and washed with ultrapure water (10000 rpm,10 minutes), and redispersed in ultrapure water to obtain rhodamine 6G@ZIF-90@ACC/PAA. (see FIG. 1B).
The morphology of the prepared rhodamine 6G@ZIF-90 and rhodamine 6G@ZIF-90@ACC/PAA was characterized by a Transmission Electron Microscope (TEM). As shown in FIGS. 1A and 1B, both rhodamine 6G@ZIF-90 and rhodamine 6G@ZIF-90@ACC/PAA are uniform nanoparticles. Rhodamine 6G@ZIF-90 nano particles are rough in surface, uniform in size and 110-150nm in average diameter. After being wrapped by polyacrylic acid/calcium chloride, the size of the rhodamine 6G@ZIF-90@ACC/PAA material is larger than that of the rhodamine 6G@ZIF-90, and the size is about 150-200nm.
Example 2:
stimulus responsiveness of double-lock MOF:
mu.L of rhodamine 6G@ZIF-90@ACC/PAA prepared in the above example (100 mg mL) was taken -1 ) Incubation was performed for 15min in 3mL of PBS (ph=4.0) solution, and morphological changes were observed by TEM (see fig. 2A). mu.L of prepared rhodamine 6G@ZIF-90@ACC/PAA (100 mg mL) was taken -1 ) Placed in 3mL of PBS (ph=4.0) solution and incubated with 5 μl of ATP (1M) solution for 15 minutes, the morphological changes were observed by TEM (see fig. 2B).
As shown in fig. 2A and 2B, the rhodamine 6g@zif-90@acc/PAA polyacrylic acid/calcium chloride hydrogel after the acid treatment was dissolved, the rhodamine 6g@zif-90 remained intact and the dimensions were the same as in fig. 1A, and the polyacrylic acid/calcium chloride hydrogel was dissolved and the rhodamine 6g@zif-90 particles were cleaved to lose the intact morphology after the acid and ATP co-treatment, demonstrating the stimulus responsiveness of the double-lock MOF.
Example 3:
stimulus responsiveness of double-locked MOF at different pH:
mu.L of rhodamine 6G@ZIF-90@ACC/PAA (1 mg mL) -1 ) Respectively adding 240 mu L of PBS buffer solutions with different pH values, adding 10 mu L of ATP (1 mM) solution, carrying out oscillation reaction for 60min, and measuring the fluorescence intensity of the solution at the excitation wavelength of 525nm and the emission wavelength of 552 nm. As can be seen from fig. 3, the fluorescence value of the double-lock MOF nanomaterial increases with time, and the release equilibrium can be reached in about 30 minutes.
Example 4:
stimulus responsiveness of double-locked MOF at different ATP concentrations:
mu.L of rhodamine 6G@ZIF-90@ACC/PAA (1 mg mL) -1 ) Add 240. Mu.L of pHAnd adding 10 mu L of ATP solution with different concentrations into PBS buffer solutions of other 4.0 and 6.0, carrying out oscillation reaction for 60min, and measuring the fluorescence intensity of the solution at the excitation wavelength of 525nm and the emission wavelength of 552 nm. As can be seen from FIG. 4, under acidic conditions, the fluorescence value increases with the increase of the ATP concentration, and the system has generated a more obvious fluorescence response at the ATP concentration of 1. Mu.M, which proves that rhodamine 6G@ZIF-90@ACC/PAA nanoparticles have sensitive ATP responsiveness.
Example 5:
fluorescence responsivity of nanocarriers prepared by different assembly methods:
1) 48.05mg of 2-imidazole-formaldehyde (0.5M), 4.79mg of rhodamine 6G (1 mM) were dissolved in 10.0mL of DMF and stirred for 15min, followed by slow addition of 5.0mL of DMF containing 0.05M zinc acetate. Then washing with ultrapure water sequentially, dispersing the product in the ultrapure water to obtain rhodamine 6G@ZIF-90 stock solution (100 mg mL) -1 ). 114mg polyacrylic acid (PAA, 0.1M), 111mg calcium chloride (0.1M) and 500. Mu.L rhodamine 6G@ZIF-90 (100 mg mL) -1 ) Added to 10.0mL of ultrapure water and stirred for 1 hour. Then, 10.0mL of 0.1M Na was added 2 CO 3 The solution was added rapidly and stirred for 1h. The resultant product was centrifuged and washed with ultrapure water, which is a material obtained in preparation method 1, i.e., example 1.
2) 114mg of polyacrylic acid (PAA, 0.1M), 111mg of calcium chloride (0.1M) and 4.79mg of rhodamine 6G (1 mM) were added to 10.0mL of ultrapure water and stirred for 1 hour. Then, 10.0mL of 0.1M Na was added 2 CO 3 The solution was added rapidly and stirred for 1h. Centrifuging the obtained product and washing with ultrapure water to obtain stock solution (100 mg mL) -1 ). 48.05mg of 2-imidazole formaldehyde (0.5M), 50. Mu.L of stock solution (100 mg mL) -1 ) Dissolved in 10.0mL DMF and stirred for 15min before slowly adding 5.0mL DMF containing 0.05M zinc acetate. Then washed with ultrapure water in this order, and the product was dispersed in ultrapure water, which is preparation method 2.
mu.L of the nanomaterial prepared in the above example was placed in 3mL of PBS (pH=4.0) solution, and 5. Mu.L of ATP (1M) solution was added to incubate for 15 minutes, and the change in fluorescence was observed, and the fluorescence was again observed for 14 days. The result shows that the target nano-carrier with double stimulus can be synthesized only by the assembly mode of the preparation method 1, and the nano-carrier has good stability, and the fluorescence value is not changed obviously after soaking for 14 days.

Claims (3)

1. A double lock MOF material, characterized by: the double-lock MOF material takes ZIF-90 as a core, and the outer part of the material wraps acid sensitive hydrogel to form a double-lock MOF material with a shell-core structure and double-lock response;
the preparation method comprises the following steps:
1) 48.05mg of 2-imidazole-formaldehyde, 4.79mg of rhodamine 6G are dissolved in 10.0mL of DMF and stirred for 15min, and then 5.0mL of DMF containing 0.05M zinc acetate is slowly added; washing with DMF, ultrapure water and ethanol in sequence, and centrifuging at 10000rpm for 5min; finally, dispersing the product in ultrapure water to obtain rhodamine 6G@ZIF-90 stock solution;
2) 114mg of polyacrylic acid, 111mg of calcium chloride and 500. Mu.L of rhodamine 6G@ZIF-90 were added to 10.0mL of ultrapure water and stirred for 1 hour; then, 10.0mL of 0.1M Na was added 2 CO 3 The solution is added and stirred for 1h; the product obtained was centrifuged at 10000rpm for 10min and washed with ultrapure water, and redispersed in ultrapure water to obtain rhodamine 6G@ZIF-90@ACC/PAA.
2. A method of preparing a double-lock MOF material according to claim 1, wherein:
1) 48.05mg of 2-imidazole-formaldehyde, 4.79mg of rhodamine 6G are dissolved in 10.0mL of DMF and stirred for 15min, and then 5.0mL of DMF containing 0.05M zinc acetate is slowly added; washing with DMF, ultrapure water and ethanol in sequence, and centrifuging at 10000rpm for 5min; finally, dispersing the product in ultrapure water to obtain rhodamine 6G@ZIF-90 stock solution;
2) 114mg of polyacrylic acid, 111mg of calcium chloride and 500. Mu.L of rhodamine 6G@ZIF-90 were added to 10.0mL of ultrapure water and stirred for 1 hour; then, 10.0mL of 0.1M Na was added 2 CO 3 The solution is added and stirred for 1h; the product obtained was centrifuged at 10000rpm for 10min and washed with ultrapure water, and redispersed in ultrapure water to obtain rhodamine 6G@ZIF-90@ACC/PAA.
3. Use of the double lock MOF material of claim 1, wherein: the use of said material as a carrier in drug delivery.
CN202210208303.7A 2022-03-04 2022-03-04 Double-lock MOF material and preparation and application thereof Active CN114652854B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210208303.7A CN114652854B (en) 2022-03-04 2022-03-04 Double-lock MOF material and preparation and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210208303.7A CN114652854B (en) 2022-03-04 2022-03-04 Double-lock MOF material and preparation and application thereof

Publications (2)

Publication Number Publication Date
CN114652854A CN114652854A (en) 2022-06-24
CN114652854B true CN114652854B (en) 2023-05-12

Family

ID=82028073

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210208303.7A Active CN114652854B (en) 2022-03-04 2022-03-04 Double-lock MOF material and preparation and application thereof

Country Status (1)

Country Link
CN (1) CN114652854B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115819165A (en) * 2022-12-20 2023-03-21 郑州大学 Copper azide composite initiating explosive block material and preparation method thereof
CN117987492A (en) * 2024-04-03 2024-05-07 中国农业科学院都市农业研究所 Preparation method of extracellular polysaccharide of yellow-green stropharia rugoso-annulata

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017078609A1 (en) * 2015-11-05 2017-05-11 Su Holding Ab One-pot synthesis of metal-organic frameworks with encapsulated target-molecule and their use
CN108456241A (en) * 2018-01-17 2018-08-28 南开大学 Porous framework material is used for the storage and transportation and preparation of biological products
CN110538345A (en) * 2019-10-11 2019-12-06 上海交通大学医学院附属第九人民医院 biological material, preparation method thereof and application thereof in bone repair
CN111265533A (en) * 2019-11-25 2020-06-12 上海纳米技术及应用国家工程研究中心有限公司 Preparation method of core-shell nanoparticles based on lipid membrane and metal organic framework
CN111269516A (en) * 2020-04-02 2020-06-12 北京航空航天大学 MXene composite gel material, preparation method and application
CN111643480A (en) * 2020-04-20 2020-09-11 武汉大学 Metal organic framework composite nano material with targeting property and pH responsiveness and preparation method and application thereof
CN112999352A (en) * 2021-03-09 2021-06-22 安徽工程大学 RGD/PTX @ ZIF-90 drug delivery system and preparation method thereof
CN113307990A (en) * 2021-06-09 2021-08-27 上海科技大学 Composite material and preparation method and application thereof
WO2021261966A1 (en) * 2020-06-26 2021-12-30 숙명여자대학교 산학협력단 Cyclodextrin-based composite composition for oral administration and method for producing same

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017078609A1 (en) * 2015-11-05 2017-05-11 Su Holding Ab One-pot synthesis of metal-organic frameworks with encapsulated target-molecule and their use
CN108456241A (en) * 2018-01-17 2018-08-28 南开大学 Porous framework material is used for the storage and transportation and preparation of biological products
CN110538345A (en) * 2019-10-11 2019-12-06 上海交通大学医学院附属第九人民医院 biological material, preparation method thereof and application thereof in bone repair
CN111265533A (en) * 2019-11-25 2020-06-12 上海纳米技术及应用国家工程研究中心有限公司 Preparation method of core-shell nanoparticles based on lipid membrane and metal organic framework
CN111269516A (en) * 2020-04-02 2020-06-12 北京航空航天大学 MXene composite gel material, preparation method and application
CN111643480A (en) * 2020-04-20 2020-09-11 武汉大学 Metal organic framework composite nano material with targeting property and pH responsiveness and preparation method and application thereof
WO2021261966A1 (en) * 2020-06-26 2021-12-30 숙명여자대학교 산학협력단 Cyclodextrin-based composite composition for oral administration and method for producing same
CN112999352A (en) * 2021-03-09 2021-06-22 安徽工程大学 RGD/PTX @ ZIF-90 drug delivery system and preparation method thereof
CN113307990A (en) * 2021-06-09 2021-08-27 上海科技大学 Composite material and preparation method and application thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ATP-triggered anticancer drug delivery;Ran Mo等;《NATURE COMMUNICATIONS》;第1-10页 *
Biodegradable Nanoparticles of Polyacrylic Acid–Stabilized Amorphous CaCO3 for Tunable pH-Responsive Drug Delivery and Enhanced Tumor Inhibition;Chengyuan Xu等;《Adv. Funct. Mater.》;第1808146页 *
Precise Localization and Simultaneous Bacterial Eradication of Biofilms Based on Nanocontainers with Successive Responsive Property toward pH and ATP;Yingwen Wang等;《Appl. Mater. Interfaces》;第8424−8435页 *
沸石咪唑酯骨架材料ZIF-90的合成及应用研究进展;李旭飞等;《化工新型材料》;第48卷(第4期);第10-16页 *

Also Published As

Publication number Publication date
CN114652854A (en) 2022-06-24

Similar Documents

Publication Publication Date Title
CN114652854B (en) Double-lock MOF material and preparation and application thereof
Abdelhamid Zeolitic imidazolate frameworks (ZIF-8) for biomedical applications: a review
Ye et al. A dual‐responsive antibiotic‐loaded nanoparticle specifically binds pathogens and overcomes antimicrobial‐resistant infections
Hu et al. Biofilm microenvironment-responsive nanoparticles for the treatment of bacterial infection
US8834917B2 (en) Nanoparticle composition and process thereof
Wang et al. pH responsive superporogen combined with PDT based on poly Ce6 ionic liquid grafted on SiO2 for combating MRSA biofilm infection
Kiprono et al. Encapsulation of E. coli in biomimetic and Fe 3 O 4-doped hydrogel: structural and viability analyses
Cai et al. An intelligent self-defensive coating based on sulfide ion responsive nanocontainers for suppression of microbiologically influenced corrosion induced by sulfate reducing bacteria
Weldick et al. Emerging nanotechnologies for targeting antimicrobial resistance
Wang et al. Responsive nanoplatform for persistent luminescence “turn-on” imaging and “on-demand” synergistic therapy of bacterial infection
Yang et al. Biopolymer coating for particle surface engineering and their biomedical applications
CN110755610B (en) Antibacterial hydrogel with aggregation-induced emission effect and preparation method thereof
CN115491363A (en) Preparation method and application of mesoporous nano material with antibacterial function
Yao et al. Pathogen‐Targeting Bimetallic Nanozymes as Ultrasonic‐Augmented ROS Generator against Multidrug Resistant Bacterial Infection
DE2709059A1 (en) PROCESS FOR IMMOBILIZING ANTIMICROBIAL ACTIVE INGREDIENTS
CN112618716B (en) Photodynamic combined lysozyme antibacterial method
KR20110115660A (en) Fluorescence nanoporous silica nanopaticle coated with lipid bilayer and method of preparing the same
CN114010619A (en) Construction and application of functional nano platform
Li et al. Nano–Bio Interactions: Biofilm‐Targeted Antibacterial Nanomaterials
Abraham et al. Biofilm inhibition and bacterial eradication by C-dots derived from polyethyleneimine-citric acid
CN110278946B (en) Bacillus thuringiensis microcapsule with ultraviolet resistance and preparation method thereof
US20080031938A1 (en) Biocidal materials for treatment against pathogens
Priya et al. S-Nitrosothiol tethered polymer hexagons: synthesis, characterisation and antibacterial effect
CN112870221B (en) Chitosan nano rhodium material and application thereof
CN111514305A (en) Carbon quantum dot-based targeted drug, and preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant